NeoESLA - Neoadjuvant Early-Stage Lung Atlas
Pathologic Response to Immunotherapy-based Neoadjuvant Treatment in Resectable Non-Small Cell Lung Cancer:
A Real-World Cohort Study and Pathology Atlas
ABSTRACT
BACKGROUND: Neoadjuvant chemoimmunotherapy (CIT) has shown promise in improving outcomes for patients with resectable NSCLC. This real-world cohort study and Pathology Atlas aim to comprehensively characterize the clinical, radiological and pathological response to CIT.
RESEARCH QUESTION: What are the pathologic response patterns to neoadjuvant chemoimmunotherapy among patients with resectable NSCLC, and which features are associated with favorable pathologic response?
STUDY DESIGN AND METHODS: This retrospective study included 50 patients with NSCLC who underwent neoadjuvant CIT at the Leiden University Medical Center between 2021 and 2025. Clinical, radiologic, surgical, pathologic, molecular, and outcome data were collected and analyzed to characterize treatment effects and define clinicopathologic, molecular and spatial tumor microenvironment features associated with pathologic response.
RESULTS: The study found that 33.3% of patients achieved a pathologic complete response (pCR) and 17.6% achieved a major pathologic response (MPR) after neoadjuvant treatment. PD-L1 expression was significantly associated with pathological response with high expression more frequent in pCR and MPR tumors. The study also identified marked heterogeneity in tumor bed architectures across pathologic response groups, with pCR tumor beds characterized by regressive fibrosis, inflammatory infiltrates and frequent cholesterol clefts.
INTERPRETATION: This real-world cohort study provides a comprehensive overview of the clinical, radiologic, and pathological features of NSCLC patients treated with neoadjuvant CIT. Additionally, the Pathology Atlas shows the heterogeneity in post-treatment responses in both primary tumors and lymph nodes seen in daily practice. These findings highlight the importance of standardized pathology-based assessments in evaluating treatment response.